drugset
drugset / Trial / NCT06427213

This is a Phase II, Open-label, Multicentre Study of Zanubrutinib-containing Regimens in Patients With Newly Diagnosed Mantle Cell Lymphoma

NCT06427213 ↗

Phase 2 Not yet recruiting 41 enrolled Henan Cancer Hospital
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a phase II, open-label, multicentre study of Zanubrutinib-containing regimens in patients with newly diagnosed mantle cell lymphoma.

Timeline

Start
2024-05-20
Primary completion
2027-12-30
Completion
2029-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Obinutuzumab Monoclonal antibody 1000 mg Intravenous
Subject Zanubrutinib Small molecule 160 mg Oral

Indications

mantle cell lymphoma